SXX
Corrigendum
ESTRO 2026
Category: Clinical: Lung
receive (neo)adjuvant chemotherapy. DFS events were analyzed using competing risk and Cox models. Resection quality was centrally reviewed. Results: At 5.0 years median follow-up, 305 DFS events were observed: 24.3% MR, 53.8% distant metastases, 12.1% both, and 9.8% deaths. PORT significantly reduced MR: 3-year MLRFS was 85.8% vs. 71.8% (HR 0.46, p=0.0001); MR-only rate: 8.6% (PORT) vs. 19.7% (observation). Multivariate analysis identified higher MR risk with no PORT (subHR 2.39, p<0.0001), squamous histology (subHR 1.76, p=0.01), LNR ≥ 25% (subHR 1.52, p=0.03), and pT3–4 tumors (HR 1.75, p=0.014). Capsular rupture at the highest nodal station was associated with increased MR risk (subHR 1.78, p=0.0051), with enhanced benefit from PORT (3-year MR: 39.2% without vs. 20.7% with). Conclusion: PORT significantly reduced MR, especially in patients with squamous histology, LNR ≥ 25%, mediastinal R1 resection, pT3-4, and possibly capsular rupture at the highest nodal station. These data support refining PORT indications using clinical and pathological risk
Proffered Paper 2093
Identifying high-risk stage IIIA-N2 NSCLC patients who may benefit from PORT: secondary analyses from the Lung ART Trial Antonin Levy 1 , Nathalie Cozic 2 , Nicolas Pourel 3 , Pascal- Alexandre Thomas 4 , Delphine Lerouge 5 , Angela Botticella 1 , Delphine Antoni 6 , Floriane Toudic 7 , Ursula Nestle 8 , Corinne Faivre-Finn 9 , Pierrz Boisselier 10 , Gérard Zalcman 11 , Olaf Mercier 12 , Eric Dansin 13 , Amaury Paumier 14 , Karine Peignaux 15 , François Thillays 16 , Jeannick Madelaine 17 , Anne Larrouy 18 , Armelle Lavolle 19 , Eric Pichon 20 , Fabrice Barlesi 21 , Cécile Le Péchoux 1 1 Radiation Oncology, Gustave Roussy, Villejuif, France. 2 Statistics, Gustave Roussy, Villejuif, France. 3 Radiation Oncology, Ste Catherine, Avignon, France. 4 Surgery, Hôpital Nord-APHM, Marseille, France. 5 Radiation Oncology, Centre Baclesse, Caen, France. 6 Radiation Oncology, Institut de cancérologie Strasbourg Europe, Strasbourg, France. 7 Radiation Oncology, Centre Armoricain de Radiothérapie, St Brieuc, France. 8 Radiation Oncology, Kliniken Maria Hilf, Moenchengladbach, Germany. 9 Radiation Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. 10 Radiation Oncology, Institut du Cancer de Montpellier, Montpellier, France. 11 Medical Oncology, Bichat-Claude Bernard Hospital, Paris, France. 12 Surgery, Marie-Lannelongue Hospital, Le Plessis Robinson, France. 13 Radiation Oncology, Centre Oscar Lambret, Lille, France. 14 Radiation Oncology, ICO, Angers, France. 15 Radiation Oncology, Centre Georges-Francois Leclerc, Dijon, France. 16 Radiation Oncology, ICO, Nantes, France. 17 Radiation Oncology, University Hospital Zurich (USZ), Zurich, France. 18 Radiation Oncology, Centre specialisé cancerologie Paris Nord, Sarcelles, France. 19 Pneumology, Tenon University Hospital, Paris, France. 20 Radiation Oncology, CHU, Tours, France. 21 Medical Oncology, Gustave Roussy, Villejuif, France Purpose/Objective: In resected stage IIIA-N2 NSCLC, mediastinal recurrence (MR) remains a key challenge despite improved systemic strategies. While the Lung ART trial showed no significant disease-free survival (DFS) benefit with postoperative radiotherapy (PORT), it halved mediastinal failures. This analysis aimed to identify subgroups at high MR risk. Material/Methods: Lung ART randomized 501 patients with completely resected pN2 NSCLC (PORT: 252; observation: 249). All had mediastinal lymph node dissection and could
models in resected IIIA-N2 NSCLC. Keywords: NSCLC, Stage 3, Adjuvant
Digital Poster 4538 Re-irradiation with overlapping fields in previously irradiated early-stage lung cancer: Modern techniques, modest adverse events Ipek Sucak, Yunus Babayigit, Oguzhan Bascik, Pantea Bayatfard, Yakup Arslan, Sumerya Duru Birgi, Serap Akyurek Radiation Oncology, Ankara University Faculty of Medicine, Ankara, Turkey Purpose/Objective: Re-irradiation is variably defined across studies; according to the ESTRO consensus, it refers to re- application of radiotherapy (RT) to a previously irradiated area or to a site at increased risk of cumulative dose-related adverse events (AE). This study aimed to evaluate treatment outcomes and AE in early-stage lung cancer patients who underwent re- irradiation with ≥ 50% isodose overlap between the first and second planning target volumes (PTVs). Material/Methods: Sixteen patients with T1N0 lung cancer who received definitive RT and later re-irradiation for locoregional recurrence (LRR) between 2020 and 2025 were retrospectively evaluated. Acute and late AE were graded using CTCAE v5.0. All re-irradiations were delivered with 4D image-guided techniques. Survival outcomes were analyzed using Kaplan–Meier, and prognostic factors with Mann–Whitney U and Chi-
Made with FlippingBook - Share PDF online